> Detailanzeige

Cloughesy, Timothy F; Brenner, Andrew; de Groot, John F; Butowski, Nicholas A; Zach, Leor; Campian, Jian L; Ellingson, Benjamin M; Freedman, Laurence S; Cohen, Yael C; Lowenton-Spier, Noa; Rachmilewitz Minei, Tamar; Fain Shmueli, Shifra; Wen, Patrick Y; Avgeropoulos, Nicholas; Beck, Joseph; Benkers, Tara; Bokstein, Felix; Brenner, Andrew; Burton, Eric; Butowski, Nicholas; Campian, Jian; Carrillo, Jose; Cloughesy, Timothy; de Groot, John; [...]

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
  • Beteiligte: Cloughesy, Timothy F; Brenner, Andrew; de Groot, John F; Butowski, Nicholas A; Zach, Leor; Campian, Jian L; Ellingson, Benjamin M; Freedman, Laurence S; Cohen, Yael C; Lowenton-Spier, Noa; Rachmilewitz Minei, Tamar; Fain Shmueli, Shifra; Wen, Patrick Y; Avgeropoulos, Nicholas; Beck, Joseph; Benkers, Tara; Bokstein, Felix; Brenner, Andrew; Burton, Eric; Butowski, Nicholas; Campian, Jian; Carrillo, Jose; Cloughesy, Timothy; de Groot, John; [...]
  • Erschienen: Oxford University Press (OUP), 2020
  • Erschienen in: Neuro-Oncology, 22 (2020) 5, Seite 705-717
  • Sprache: Englisch
  • DOI: 10.1093/neuonc/noz232
  • ISSN: 1522-8517; 1523-5866
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractBackgroundOfranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab.MethodsThis pivotal phase III randomized, controlled trial compared the efficacy and safety of upfront combination of VB-111 and bevacizumab versus bevacizumab monotherapy. Patients were randomized 1:1 to receive VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks (combination arm) or bevacizumab monotherapy (control arm). The primary endpoint was overall survival (OS), and secondary endpoints were objective response rate (ORR) by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS).ResultsEnrolled were 256 patients at 57 sites. Median exposure to VB-111 was 4 months. The study did not meet its primary or secondary goals. Median OS was 6.8 versus 7.9 months in the combination versus control arm (hazard ratio, 1.20; 95% CI: 0.91–1.59; P = 0.19) and ORR was 27.3% versus 21.9% (P = 0.26). A higher rate of grades 3–5 adverse events was reported in the combination arm (67% vs 40%), mainly attributed to a higher rate of CNS and flu-like/fever events. Trends for improved survival with combination treatment were seen in the subgroup of patients with smaller tumors and in patients who had a posttreatment febrile reaction.ConclusionsIn this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II results.Clinical trials registrationNCT02511405
  • Zugangsstatus: Freier Zugang